ZA200201403B - Composition comprising a tramadol material and an anticonvulsant drug. - Google Patents
Composition comprising a tramadol material and an anticonvulsant drug. Download PDFInfo
- Publication number
- ZA200201403B ZA200201403B ZA200201403A ZA200201403A ZA200201403B ZA 200201403 B ZA200201403 B ZA 200201403B ZA 200201403 A ZA200201403 A ZA 200201403A ZA 200201403 A ZA200201403 A ZA 200201403A ZA 200201403 B ZA200201403 B ZA 200201403B
- Authority
- ZA
- South Africa
- Prior art keywords
- tramadol
- composition
- ratio
- substance
- fraction
- Prior art date
Links
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 title claims description 176
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 title claims description 175
- 229960004380 tramadol Drugs 0.000 title claims description 167
- 239000000463 material Substances 0.000 title claims description 120
- 239000000203 mixture Substances 0.000 title claims description 116
- 239000001961 anticonvulsive agent Substances 0.000 title claims description 110
- 238000000034 method Methods 0.000 claims description 64
- 208000002193 Pain Diseases 0.000 claims description 63
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims description 56
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims description 56
- 229960004394 topiramate Drugs 0.000 claims description 56
- 230000036407 pain Effects 0.000 claims description 55
- 239000008194 pharmaceutical composition Substances 0.000 claims description 55
- 239000000126 substance Substances 0.000 claims description 45
- OLBWFRRUHYQABZ-MRVPVSSYSA-N carisbamate Chemical compound NC(=O)OC[C@@H](O)C1=CC=CC=C1Cl OLBWFRRUHYQABZ-MRVPVSSYSA-N 0.000 claims description 33
- PPKXEPBICJTCRU-XMZRARIVSA-N (R,R)-tramadol hydrochloride Chemical compound Cl.COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 PPKXEPBICJTCRU-XMZRARIVSA-N 0.000 claims description 30
- 229960003107 tramadol hydrochloride Drugs 0.000 claims description 30
- 229960001848 lamotrigine Drugs 0.000 claims description 29
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 claims description 29
- 229960002870 gabapentin Drugs 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 27
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims description 19
- 238000001356 surgical procedure Methods 0.000 claims description 18
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 claims description 15
- -1 N-oxide derivative of (1R,2R)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-cyclohexanol Chemical class 0.000 claims description 14
- 229960002036 phenytoin Drugs 0.000 claims description 14
- 208000012902 Nervous system disease Diseases 0.000 claims description 13
- 230000000926 neurological effect Effects 0.000 claims description 13
- 208000020016 psychiatric disease Diseases 0.000 claims description 13
- 241000124008 Mammalia Species 0.000 claims description 11
- UWJUQVWARXYRCG-HIFRSBDPSA-N O-Desmethyltramadol Chemical compound CN(C)C[C@H]1CCCC[C@]1(O)C1=CC=CC(O)=C1 UWJUQVWARXYRCG-HIFRSBDPSA-N 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 10
- 229960000604 valproic acid Drugs 0.000 claims description 10
- 208000004296 neuralgia Diseases 0.000 claims description 8
- 208000021722 neuropathic pain Diseases 0.000 claims description 8
- 208000028867 ischemia Diseases 0.000 claims description 7
- 230000004770 neurodegeneration Effects 0.000 claims description 7
- 230000009692 acute damage Effects 0.000 claims description 6
- 208000014674 injury Diseases 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 230000008733 trauma Effects 0.000 claims description 6
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims description 5
- 208000000094 Chronic Pain Diseases 0.000 claims description 5
- AJXPJJZHWIXJCJ-UHFFFAOYSA-N Methsuximide Chemical compound O=C1N(C)C(=O)CC1(C)C1=CC=CC=C1 AJXPJJZHWIXJCJ-UHFFFAOYSA-N 0.000 claims description 5
- 208000016285 Movement disease Diseases 0.000 claims description 5
- 150000001204 N-oxides Chemical class 0.000 claims description 5
- XPFRXWCVYUEORT-UHFFFAOYSA-N Phenacemide Chemical compound NC(=O)NC(=O)CC1=CC=CC=C1 XPFRXWCVYUEORT-UHFFFAOYSA-N 0.000 claims description 5
- WLWFNJKHKGIJNW-UHFFFAOYSA-N Phensuximide Chemical compound O=C1N(C)C(=O)CC1C1=CC=CC=C1 WLWFNJKHKGIJNW-UHFFFAOYSA-N 0.000 claims description 5
- HMHVCUVYZFYAJI-UHFFFAOYSA-N Sultiame Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1S(=O)(=O)CCCC1 HMHVCUVYZFYAJI-UHFFFAOYSA-N 0.000 claims description 5
- 229960000571 acetazolamide Drugs 0.000 claims description 5
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 claims description 5
- 208000005298 acute pain Diseases 0.000 claims description 5
- 229940049706 benzodiazepine Drugs 0.000 claims description 5
- 229960000623 carbamazepine Drugs 0.000 claims description 5
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 5
- 229960001403 clobazam Drugs 0.000 claims description 5
- CXOXHMZGEKVPMT-UHFFFAOYSA-N clobazam Chemical compound O=C1CC(=O)N(C)C2=CC=C(Cl)C=C2N1C1=CC=CC=C1 CXOXHMZGEKVPMT-UHFFFAOYSA-N 0.000 claims description 5
- 229960003120 clonazepam Drugs 0.000 claims description 5
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 claims description 5
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims description 5
- 229940064790 dilantin Drugs 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 229940028937 divalproex sodium Drugs 0.000 claims description 5
- 229960002767 ethosuximide Drugs 0.000 claims description 5
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 claims description 5
- 229960003533 ethotoin Drugs 0.000 claims description 5
- SZQIFWWUIBRPBZ-UHFFFAOYSA-N ethotoin Chemical compound O=C1N(CC)C(=O)NC1C1=CC=CC=C1 SZQIFWWUIBRPBZ-UHFFFAOYSA-N 0.000 claims description 5
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 claims description 5
- 229960001596 famotidine Drugs 0.000 claims description 5
- 230000004968 inflammatory condition Effects 0.000 claims description 5
- 229940098829 magnesium sulfate injection Drugs 0.000 claims description 5
- 229960000906 mephenytoin Drugs 0.000 claims description 5
- GMHKMTDVRCWUDX-UHFFFAOYSA-N mephenytoin Chemical compound C=1C=CC=CC=1C1(CC)NC(=O)N(C)C1=O GMHKMTDVRCWUDX-UHFFFAOYSA-N 0.000 claims description 5
- 229960003729 mesuximide Drugs 0.000 claims description 5
- 229960003396 phenacemide Drugs 0.000 claims description 5
- 229960002695 phenobarbital Drugs 0.000 claims description 5
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 claims description 5
- 229960004227 phensuximide Drugs 0.000 claims description 5
- 229960002790 phenytoin sodium Drugs 0.000 claims description 5
- 229960001233 pregabalin Drugs 0.000 claims description 5
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims description 5
- 229960002393 primidone Drugs 0.000 claims description 5
- DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 claims description 5
- 229960002752 progabide Drugs 0.000 claims description 5
- IBALRBWGSVJPAP-HEHNFIMWSA-N progabide Chemical compound C=1C(F)=CC=C(O)C=1C(=N/CCCC(=O)N)/C1=CC=C(Cl)C=C1 IBALRBWGSVJPAP-HEHNFIMWSA-N 0.000 claims description 5
- FJPYVLNWWICYDW-UHFFFAOYSA-M sodium;5,5-diphenylimidazolidin-1-ide-2,4-dione Chemical compound [Na+].O=C1[N-]C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 FJPYVLNWWICYDW-UHFFFAOYSA-M 0.000 claims description 5
- 239000012453 solvate Substances 0.000 claims description 5
- 229960002573 sultiame Drugs 0.000 claims description 5
- 229960004453 trimethadione Drugs 0.000 claims description 5
- IRYJRGCIQBGHIV-UHFFFAOYSA-N trimethadione Chemical compound CN1C(=O)OC(C)(C)C1=O IRYJRGCIQBGHIV-UHFFFAOYSA-N 0.000 claims description 5
- XWLUWCNOOVRFPX-UHFFFAOYSA-N Fosphenytoin Chemical compound O=C1N(COP(O)(=O)O)C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 XWLUWCNOOVRFPX-UHFFFAOYSA-N 0.000 claims description 4
- FWJKNZONDWOGMI-UHFFFAOYSA-N Metharbital Chemical compound CCC1(CC)C(=O)NC(=O)N(C)C1=O FWJKNZONDWOGMI-UHFFFAOYSA-N 0.000 claims description 4
- VQASKUSHBVDKGU-UHFFFAOYSA-N Paramethadione Chemical compound CCC1(C)OC(=O)N(C)C1=O VQASKUSHBVDKGU-UHFFFAOYSA-N 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 229960000693 fosphenytoin Drugs 0.000 claims description 4
- 229960002057 metharbital Drugs 0.000 claims description 4
- 229960003274 paramethadione Drugs 0.000 claims description 4
- 206010001540 Akathisia Diseases 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000020925 Bipolar disease Diseases 0.000 claims description 3
- 208000006561 Cluster Headache Diseases 0.000 claims description 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 3
- 208000019695 Migraine disease Diseases 0.000 claims description 3
- 206010027603 Migraine headaches Diseases 0.000 claims description 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 3
- 208000001431 Psychomotor Agitation Diseases 0.000 claims description 3
- 208000028017 Psychotic disease Diseases 0.000 claims description 3
- 208000005793 Restless legs syndrome Diseases 0.000 claims description 3
- 206010041250 Social phobia Diseases 0.000 claims description 3
- 208000026137 Soft tissue injury Diseases 0.000 claims description 3
- 206010044565 Tremor Diseases 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 230000007850 degeneration Effects 0.000 claims description 3
- 230000003111 delayed effect Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 claims description 3
- 210000000653 nervous system Anatomy 0.000 claims description 3
- 230000002981 neuropathic effect Effects 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 3
- 208000037821 progressive disease Diseases 0.000 claims description 3
- 238000011084 recovery Methods 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 206010044652 trigeminal neuralgia Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 4
- ALARQZQTBTVLJV-UHFFFAOYSA-N mephobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)N(C)C1=O ALARQZQTBTVLJV-UHFFFAOYSA-N 0.000 claims 3
- 229960001703 methylphenobarbital Drugs 0.000 claims 3
- 208000001294 Nociceptive Pain Diseases 0.000 claims 2
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 2
- 208000037816 tissue injury Diseases 0.000 claims 2
- TVYLLZQTGLZFBW-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol Chemical compound COC1=CC=CC(C2(O)C(CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-UHFFFAOYSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 description 28
- 229940079593 drug Drugs 0.000 description 24
- 230000003574 anti-allodynic effect Effects 0.000 description 16
- 241000700159 Rattus Species 0.000 description 15
- 230000000694 effects Effects 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000000725 suspension Substances 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 7
- 229960003965 antiepileptics Drugs 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 206010022998 Irritability Diseases 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000000996 additive effect Effects 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 6
- 230000001773 anti-convulsant effect Effects 0.000 description 6
- 230000003502 anti-nociceptive effect Effects 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 210000002683 foot Anatomy 0.000 description 6
- 239000012458 free base Substances 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 239000000014 opioid analgesic Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 208000004454 Hyperalgesia Diseases 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 229940035676 analgesics Drugs 0.000 description 5
- 239000000730 antalgic agent Substances 0.000 description 5
- 239000000890 drug combination Substances 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 229940005483 opioid analgesics Drugs 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 208000025966 Neurological disease Diseases 0.000 description 4
- 230000036592 analgesia Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- 210000001032 spinal nerve Anatomy 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 206010053552 allodynia Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000013066 combination product Substances 0.000 description 3
- 229940127555 combination product Drugs 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229960001680 ibuprofen Drugs 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229940121367 non-opioid analgesics Drugs 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000011885 synergistic combination Substances 0.000 description 3
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
- HBXKSXMNNGHBEA-ZBFHGGJFSA-N 1-[(1r,2r)-2-hydroxy-2-(3-methoxyphenyl)cyclohexyl]-n,n-dimethylmethanamine oxide Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)C[N+](C)(C)[O-])=C1 HBXKSXMNNGHBEA-ZBFHGGJFSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 2
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 2
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 2
- 206010038678 Respiratory depression Diseases 0.000 description 2
- 230000003556 anti-epileptic effect Effects 0.000 description 2
- 229940125681 anticonvulsant agent Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229960004126 codeine Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229960002737 fructose Drugs 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 210000000548 hind-foot Anatomy 0.000 description 2
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 2
- 229960000240 hydrocodone Drugs 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 230000003533 narcotic effect Effects 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000003791 organic solvent mixture Substances 0.000 description 2
- 229960002085 oxycodone Drugs 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 2
- FGCFTLWVTWVAPJ-UHFFFAOYSA-N 1-(3-methoxyphenyl)cyclohexan-1-ol Chemical compound COC1=CC=CC(C2(O)CCCCC2)=C1 FGCFTLWVTWVAPJ-UHFFFAOYSA-N 0.000 description 1
- IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- 235000003625 Acrocomia mexicana Nutrition 0.000 description 1
- 244000202285 Acrocomia mexicana Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 206010061296 Motor dysfunction Diseases 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 229940127450 Opioid Agonists Drugs 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000011102 Thera Species 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
- 229960001113 butorphanol Drugs 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- QGTYWWGEWOBMAK-UHFFFAOYSA-N chlormephos Chemical compound CCOP(=S)(OCC)SCCl QGTYWWGEWOBMAK-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940073755 combination tramadol Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 229960000920 dihydrocodeine Drugs 0.000 description 1
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009963 fulling Methods 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003612 morphinomimetic agent Substances 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 229940124637 non-opioid analgesic drug Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000003402 opiate agonist Substances 0.000 description 1
- 229940124636 opioid drug Drugs 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000003594 spinal ganglia Anatomy 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15020199P | 1999-08-20 | 1999-08-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200201403B true ZA200201403B (en) | 2003-07-30 |
Family
ID=22533492
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200201403A ZA200201403B (en) | 1999-08-20 | 2002-02-19 | Composition comprising a tramadol material and an anticonvulsant drug. |
Country Status (31)
Country | Link |
---|---|
US (1) | US6562865B1 (xx) |
EP (1) | EP1210118B1 (xx) |
JP (1) | JP4977297B2 (xx) |
KR (1) | KR100758609B1 (xx) |
CN (1) | CN1198651C (xx) |
AR (1) | AR032132A1 (xx) |
AT (1) | ATE284223T1 (xx) |
AU (1) | AU782759B2 (xx) |
BG (1) | BG65996B1 (xx) |
BR (1) | BRPI0013439B8 (xx) |
CA (1) | CA2381797C (xx) |
CO (1) | CO5190667A1 (xx) |
CR (1) | CR6593A (xx) |
CZ (1) | CZ2002524A3 (xx) |
DE (1) | DE60016602T2 (xx) |
EA (1) | EA006598B1 (xx) |
ES (1) | ES2234651T3 (xx) |
HU (1) | HUP0203198A3 (xx) |
IL (2) | IL148019A0 (xx) |
MX (1) | MXPA02001820A (xx) |
MY (1) | MY136985A (xx) |
NO (1) | NO332342B1 (xx) |
NZ (1) | NZ517106A (xx) |
PL (1) | PL213323B1 (xx) |
PT (1) | PT1210118E (xx) |
SK (1) | SK286621B6 (xx) |
TR (1) | TR200201067T2 (xx) |
TW (1) | TWI259769B (xx) |
UA (1) | UA75868C2 (xx) |
WO (1) | WO2001013904A2 (xx) |
ZA (1) | ZA200201403B (xx) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69226624T3 (de) | 1991-09-06 | 2009-11-05 | Ortho-Mcneil Pharmaceutical, Inc. | Zusammensetzung, die eine tramadol-verbindung und acetaminophen enthält, und ihre verwendung |
US7164034B2 (en) | 1999-06-10 | 2007-01-16 | Pfizer Inc. | Alpha2delta ligands for fibromyalgia and other disorders |
ATE284223T1 (de) | 1999-08-20 | 2004-12-15 | Ortho Mcneil Pharm Inc | Zusammensetzung enthaltend ein tramadol und ein antikonvulsives arzneimittel |
DE19940740A1 (de) * | 1999-08-31 | 2001-03-01 | Gruenenthal Gmbh | Pharmazeutische Salze |
DE10049483A1 (de) * | 2000-09-29 | 2002-05-02 | Gruenenthal Gmbh | Substituierte 1-Aminobutan-3-ol-Derivate |
AU2002336765B2 (en) * | 2001-09-24 | 2007-12-20 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful for the treatment of restless limb syndrome and periodic limb movement disorder |
US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
US7790905B2 (en) | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
JP2005518439A (ja) * | 2002-02-26 | 2005-06-23 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 抗痙攣性誘導体と抗片頭痛薬を含んで成る片頭痛治療用共治療薬 |
CA2477923C (en) | 2002-03-01 | 2021-02-23 | University Of South Florida | Multiple-component solid phases containing at least one active pharmaceutical ingredient |
EP1364649A1 (en) * | 2002-05-23 | 2003-11-26 | Cilag AG | Adduct of topiramate and tramadol hydrochioride and uses thereof |
AU2003243699B2 (en) | 2002-06-21 | 2009-01-15 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions with improved dissolution |
WO2004043374A2 (en) | 2002-11-06 | 2004-05-27 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for treating cancer using proteasome inhibitors |
US20060147527A1 (en) * | 2002-12-13 | 2006-07-06 | Cilag Ag | Controlled release preparations comprising tramadol and topiramate |
US8183290B2 (en) | 2002-12-30 | 2012-05-22 | Mcneil-Ppc, Inc. | Pharmaceutically acceptable propylene glycol solvate of naproxen |
KR101043789B1 (ko) * | 2003-03-31 | 2011-06-27 | (주)에이스딕시오 | 디지털 신호 처리를 이용한 전력 측정기 및 그 전력 측정 방법과 그 방법을 수행하는 프로그램을 기록한 컴퓨터로 읽을 수 있는 기록매체 |
US20090214426A1 (en) * | 2004-05-19 | 2009-08-27 | Laura Corradini | Assay Method |
AR049646A1 (es) * | 2004-06-16 | 2006-08-23 | Janssen Pharmaceutica Nv | Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados |
MY147767A (en) * | 2004-06-16 | 2013-01-31 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
ATE400565T1 (de) * | 2004-08-24 | 2008-07-15 | Janssen Pharmaceutica Nv | Als antikonvulsive mittel geeignete neue benzokondensierte heteroarylsulfamidderivate |
KR20110049901A (ko) * | 2004-10-15 | 2011-05-12 | 얀센 파마슈티카 엔.브이. | 신경변성 질환 치료에 사용하는 카바메이트 화합물 |
JP2008536928A (ja) * | 2005-04-19 | 2008-09-11 | アルザ・コーポレーシヨン | トラマドール及び、ガバペンチンを含んでなる物質、の組み合わせ物 |
EP1881959A1 (en) | 2005-05-20 | 2008-01-30 | Janssen Pharmaceutica N.V. | Process for preparation of sulfamide derivatives |
US20070021500A1 (en) * | 2005-07-12 | 2007-01-25 | Twyman Roy E | Methods for neuroprotection |
CA2625210A1 (en) * | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
MXPA05011735A (es) * | 2005-11-01 | 2007-04-30 | Leopoldo Espinosa Abdala | Composiciones farmaceuticas que comprenden combinaciones de analgesicos y anticonvulsivantes para el tratamiento del dolor agudo y cronico. |
US8937096B2 (en) | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
US8716231B2 (en) | 2005-12-19 | 2014-05-06 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain |
US20070155823A1 (en) * | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents |
US8492431B2 (en) * | 2005-12-19 | 2013-07-23 | Janssen Pharmaceutica, N.V. | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity |
US8497298B2 (en) * | 2005-12-19 | 2013-07-30 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
US8691867B2 (en) * | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
US20070155827A1 (en) * | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression |
US20070191452A1 (en) * | 2006-02-15 | 2007-08-16 | Smith-Swintosky Virginia L | Use of benzo-heteroaryl sulfamide derivatives for the treatment of pain |
US20070191461A1 (en) * | 2006-02-15 | 2007-08-16 | Smith-Swintosky Virginia L | Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine |
US20070191449A1 (en) * | 2006-02-15 | 2007-08-16 | Smith-Swintosky Virginia L | Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression |
US20070191474A1 (en) * | 2006-02-15 | 2007-08-16 | Smith-Swintosky Virginia L | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine |
JP2009537635A (ja) * | 2006-05-19 | 2009-10-29 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 癲癇の処置のための共同−療法 |
TW200812574A (en) * | 2006-05-19 | 2008-03-16 | Janssen Pharmaceutica Nv | Co-therapy for the treatment of epilepsy and related disorders |
EA027836B1 (ru) * | 2006-06-15 | 2017-09-29 | ЮСиБи ФАРМА ГМБХ | Фармацевтическая комбинация для профилактики, облегчения и/или лечения приступов эпилепсии и ее применение |
US9744137B2 (en) * | 2006-08-31 | 2017-08-29 | Supernus Pharmaceuticals, Inc. | Topiramate compositions and methods of enhancing its bioavailability |
JP2010508279A (ja) * | 2006-10-27 | 2010-03-18 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 破壊的行動障害の処置法 |
ES2555066T3 (es) | 2006-11-17 | 2015-12-28 | Supernus Pharmaceuticals, Inc. | Formulaciones de liberación sostenida de topiramato |
CN101553204B (zh) * | 2006-12-04 | 2013-10-30 | 苏佩努斯制药公司 | 托吡酯的增强的立即释放制剂 |
US20090076128A1 (en) * | 2007-09-15 | 2009-03-19 | Protia Llc | Deuterium-enriched topiramate |
US8263652B2 (en) * | 2007-10-31 | 2012-09-11 | Sk Biopharmaceuticals Co., Ltd. | Stabilized pediatric suspension of carisbamate |
US8356315B2 (en) * | 2007-12-03 | 2013-01-15 | Koncelik Jr Lawrence J | Setting television default channel |
EP2250148B1 (en) | 2008-01-25 | 2016-08-17 | XenoPort, Inc. | Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use |
WO2009094577A2 (en) | 2008-01-25 | 2009-07-30 | Xenoport, Inc. | Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use |
TWI380812B (zh) | 2008-01-25 | 2013-01-01 | Xenoport Inc | (3s)-胺甲基-5-甲基己酸前藥之晶形及使用方法 |
US20090247617A1 (en) * | 2008-03-26 | 2009-10-01 | Abdel-Magid Ahmed F | Process for the preparation of benzo-fused heteroaryl sulfamates |
US20090247616A1 (en) * | 2008-03-26 | 2009-10-01 | Smith-Swintosky Virginia L | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety |
SG157299A1 (en) | 2008-05-09 | 2009-12-29 | Agency Science Tech & Res | Diagnosis and treatment of kawasaki disease |
US8809385B2 (en) | 2008-06-23 | 2014-08-19 | Janssen Pharmaceutica Nv | Crystalline form of (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide |
US20100003322A1 (en) * | 2008-07-03 | 2010-01-07 | Lai Felix S | Enteric coated hydrophobic matrix formulation |
US8815939B2 (en) | 2008-07-22 | 2014-08-26 | Janssen Pharmaceutica Nv | Substituted sulfamide derivatives |
LT2735338T (lt) | 2008-09-05 | 2019-04-10 | Grünenthal GmbH | 3-(3-dimetilamino-1-etil-2-metil-propil)-fenolio ir pregabalino arba gabapentino farmacinis derinys |
US20100190752A1 (en) | 2008-09-05 | 2010-07-29 | Gruenenthal Gmbh | Pharmaceutical Combination |
WO2011023392A1 (en) | 2009-08-28 | 2011-03-03 | Grünenthal GmbH | Pharmaceutical combination comprising 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol or 6-dimethylaminomethyl-1-(3-hydroxy-phenyl)-cyclohexane-1,3-diol and an antiepileptic |
EP2383255A1 (en) | 2010-04-28 | 2011-11-02 | Lacer, S.A. | New compounds, synthesis and use thereof in the treatment of pain |
EP2599487B1 (en) | 2010-07-30 | 2015-04-01 | Toray Industries, Inc. | Therapeutic agent or prophylactic agent for neuropathic pain |
EP2530072A1 (en) | 2011-06-03 | 2012-12-05 | Lacer, S.A. | New compounds, synthesis and use thereof in the treatment of pain |
US10702485B2 (en) * | 2011-07-09 | 2020-07-07 | Syntrix Biosystems Inc. | Compositions and methods for overcoming resistance to tramadol |
RU2533979C1 (ru) * | 2013-03-11 | 2014-11-27 | государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации | Способ лечения центральных стенозирующих злокачественных опухолей трахеи и бронхов |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
DE102013009114A1 (de) * | 2013-05-29 | 2014-12-04 | Franz Gerstheimer | Pharmazeutische Zusammensetzung zur Überwindung von Metabolisierungsproblemen |
KR20180093086A (ko) | 2016-01-06 | 2018-08-20 | 론자 리미티드 | 개선된 생산을 위한 단백질 분해의 억제 |
US11464756B1 (en) | 2017-05-19 | 2022-10-11 | Jerry Darm | Mecuna pruriens, L-DOPA and 5-HTP based dietary supplements, pharmaceutical formulations and uses thereof |
MX2020009740A (es) | 2018-03-20 | 2021-01-20 | Abraxis Bioscience Llc | Metodos para el tratamiento de trastornos del sistema nervioso central mediante la administracion de nanoparticulas de un inhibidor del objetivo de la rapamicina en mamiferos (mtor) y una albumina. |
WO2020044070A1 (es) | 2018-08-30 | 2020-03-05 | Grünenthal GmbH | Combinación farmacéutica sinérgica que comprende tramadol clorhidrato y pregabalina, y su uso para el tratamiento del dolor neuropático |
JP7257091B2 (ja) * | 2019-06-27 | 2023-04-13 | 沼澤 敏彦 | 認知症の治療及び予防薬 |
US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3652589A (en) | 1967-07-27 | 1972-03-28 | Gruenenthal Chemie | 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols |
US3562589A (en) * | 1968-09-09 | 1971-02-09 | Ite Imperial Corp | Electrically resetting undervoltage trip for circuit breakers |
US4513006A (en) * | 1983-09-26 | 1985-04-23 | Mcneil Lab., Inc. | Anticonvulsant sulfamate derivatives |
US4587252A (en) * | 1984-12-18 | 1986-05-06 | Brighton Pharmaceutical, Inc. | Hydrocodone/ibuprofen pharmaceutical compositions and method |
US4569937A (en) * | 1985-02-11 | 1986-02-11 | E. I. Du Pont De Nemours And Company | Analgesic mixture of oxycodone and ibuprofen |
DE69226624T3 (de) * | 1991-09-06 | 2009-11-05 | Ortho-Mcneil Pharmaceutical, Inc. | Zusammensetzung, die eine tramadol-verbindung und acetaminophen enthält, und ihre verwendung |
CA2077637C (en) | 1991-09-06 | 2007-01-09 | Robert B. Raffa | Compositions comprising a tramadol material and any of codeine, oxycodone or hydrocodone and their use |
US5516803A (en) | 1991-10-30 | 1996-05-14 | Mcneilab, Inc. | Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug |
GB9417532D0 (en) | 1994-08-31 | 1994-10-19 | Zeneca Ltd | Aromatic compounds |
TR199900298T2 (xx) | 1996-08-14 | 1999-05-21 | G.D. Searle &Co. | 4-(5-Metil-3-fenilizoksazol-4-il) BenzenS�lfonamidin kristal halinde bi�imi. |
ATE293458T1 (de) * | 1996-08-23 | 2005-05-15 | Algos Pharm Corp | Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen |
US5760007A (en) * | 1997-07-16 | 1998-06-02 | Ortho Pharmaceutical Corporation | Anticonvulsant derivatives useful in treating neuropathic pain |
DE69827149T2 (de) * | 1997-08-15 | 2006-03-09 | Fairbanks, Carolyn Ann, Rochester | Agmatin für die behandlung neuropathischer schmerzen |
PL339142A1 (en) * | 1997-09-08 | 2000-12-04 | Warner Lambert Co | Analgesic compositions containing anticonvulsants and method of using them |
ATE284223T1 (de) | 1999-08-20 | 2004-12-15 | Ortho Mcneil Pharm Inc | Zusammensetzung enthaltend ein tramadol und ein antikonvulsives arzneimittel |
-
2000
- 2000-08-09 AT AT00957321T patent/ATE284223T1/de active
- 2000-08-09 EA EA200200183A patent/EA006598B1/ru not_active IP Right Cessation
- 2000-08-09 DE DE60016602T patent/DE60016602T2/de not_active Expired - Lifetime
- 2000-08-09 TR TR2002/01067T patent/TR200201067T2/xx unknown
- 2000-08-09 WO PCT/US2000/021622 patent/WO2001013904A2/en active IP Right Grant
- 2000-08-09 KR KR1020027002005A patent/KR100758609B1/ko active IP Right Grant
- 2000-08-09 JP JP2001518042A patent/JP4977297B2/ja not_active Expired - Lifetime
- 2000-08-09 IL IL14801900A patent/IL148019A0/xx unknown
- 2000-08-09 BR BRPI0013439-2 patent/BRPI0013439B8/pt not_active IP Right Cessation
- 2000-08-09 SK SK226-2002A patent/SK286621B6/sk not_active IP Right Cessation
- 2000-08-09 CZ CZ2002524A patent/CZ2002524A3/cs unknown
- 2000-08-09 US US09/634,904 patent/US6562865B1/en not_active Expired - Lifetime
- 2000-08-09 NZ NZ517106A patent/NZ517106A/en not_active IP Right Cessation
- 2000-08-09 AU AU68958/00A patent/AU782759B2/en not_active Expired
- 2000-08-09 CA CA002381797A patent/CA2381797C/en not_active Expired - Fee Related
- 2000-08-09 CN CNB008144990A patent/CN1198651C/zh not_active Expired - Lifetime
- 2000-08-09 EP EP00957321A patent/EP1210118B1/en not_active Expired - Lifetime
- 2000-08-09 MX MXPA02001820A patent/MXPA02001820A/es active IP Right Grant
- 2000-08-09 PL PL353266A patent/PL213323B1/pl unknown
- 2000-08-09 PT PT00957321T patent/PT1210118E/pt unknown
- 2000-08-09 ES ES00957321T patent/ES2234651T3/es not_active Expired - Lifetime
- 2000-08-09 HU HU0203198A patent/HUP0203198A3/hu unknown
- 2000-08-18 CO CO00062273A patent/CO5190667A1/es active IP Right Grant
- 2000-08-18 MY MYPI20003811A patent/MY136985A/en unknown
- 2000-08-18 AR ARP000104303A patent/AR032132A1/es unknown
- 2000-09-08 UA UA2002021306A patent/UA75868C2/uk unknown
- 2000-09-18 TW TW089116948A patent/TWI259769B/zh not_active IP Right Cessation
-
2002
- 2002-02-05 IL IL148019A patent/IL148019A/en active IP Right Grant
- 2002-02-13 NO NO20020728A patent/NO332342B1/no not_active IP Right Cessation
- 2002-02-19 ZA ZA200201403A patent/ZA200201403B/en unknown
- 2002-02-19 BG BG106420A patent/BG65996B1/bg unknown
- 2002-02-20 CR CR6593A patent/CR6593A/es not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1210118B1 (en) | Composition comprising a tramadol material and an anticonvulsant drug | |
AU651247B2 (en) | Composition comprising a tramadol material and acetaminophen and its use | |
DE69733081T2 (de) | Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen | |
KR100236666B1 (ko) | 트라마돌 및 코데인, 옥시코돈 또는 하이드로코돈을 함유하는 조성물 및 그의 용도 | |
Bartolini et al. | Analgesic and antineuropathic drugs acting through central cholinergic mechanisms | |
US8710040B2 (en) | Pharmaceutical composition comprising gabapentin or an analogue thereof and an α-aminoamide and its analgesic use | |
US20030013689A1 (en) | Method for treating pain | |
AU3384200A (en) | Composition comprising a tramadol material and a selective cox-2 inhibitor drug | |
IE58314B1 (en) | Pharmaceutical products providing enhanced analgasia | |
NO302736B1 (no) | Farmasöytisk preparat omfattende tramadol og ibuprofen | |
US20100256179A1 (en) | Combination therapy for pain in painful diabetic neuropathy | |
WO1995031194A1 (en) | Compositions for treatment of chronic inflammatory diseases | |
KR20090018863A (ko) | 통증성 의학적 상태를 위한 치료제 조합 | |
MXPA05011735A (es) | Composiciones farmaceuticas que comprenden combinaciones de analgesicos y anticonvulsivantes para el tratamiento del dolor agudo y cronico. | |
JPH05132430A (ja) | 薬物従属症及び禁断症状の治療に関するグリシン/nmdaレセプターリガンドの用法 | |
EP0371085A1 (en) | Dextromethorphan potentiator for anticonvulsant composition and method | |
Doyle et al. | Investigation of the actions and antagonist activity of some polyamine analogues in vivo |